“Various different doses of bevacizumab have been used in the published evidence sources, as well as different dose frequency schedules. The issue of optimal dose and frequency of bevacizumab has still not been conclusively resolved however this submission specifically relates to a standard dose of 1.25 mg of bevacizumab, and this is the dose most commonly used in published studies.” The 1.25 mg dosage is administered monthly.
“Pre-packaged syringes of bevacizumab for intravitreal use are available to purchase from special manufacturing units. Moorfields Pharmaceuticals, of Moorfields NHS hospital, can supply syringes of 1.25 mg in 0.05 ml at £85 per syringe, excluding VAT and delivery charges.
We prepare in BSC of the left over of the CRC regimen including Bevacizumab in the regimen, with the all the precautions.